Insider · CIK 0001551965

Aggarwal Gaurav

Reports to the SEC for 5 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001551965

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-08-25	UNCYUnicycive Therapeutics, Inc.C Conversion	Director	CConversion	+653K sh	—	—	1,789,915
2025-08-25	UNCYUnicycive Therapeutics, Inc. · Series A-2 Prime Preferred StockD Disposition to Issuer	Director	DDisposition to Issuer	−3,199.21 sh	$1000.00	−$3.2M	0
2025-07-28	UNCYUnicycive Therapeutics, Inc. · Stock OptionsA Award	Director	AAward	+21.2K sh	—	—	39,200
2025-05-21	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+180K sh	—	—	180,000
2025-02-18	UNCYUnicycive Therapeutics, Inc.C Conversion	Director	CConversion	+1.4M sh	—	—	11,370,152
2025-02-18	UNCYUnicycive Therapeutics, Inc. · Series A-2 Prime Preferred StockD Disposition to Issuer	Director	DDisposition to Issuer	−686 sh	$1000.00	−$686K	3,119.21
2024-10-09	UNCYUnicycive Therapeutics, Inc.C Conversion	Director	CConversion	+5.5M sh	—	—	9,970,152
2024-10-09	UNCYUnicycive Therapeutics, Inc. · Series A-2 Prime Preferred StockD Disposition to Issuer	Director	DDisposition to Issuer	−2,695 sh	$1000.00	−$2.7M	3,885.21
2024-05-09	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+180K sh	—	—	180,000
2023-12-29	GERNGERON CORPA Award	Director	AAward	+1,970 sh	—	—	1,970
2023-11-26	GERNGERON CORP · Stock Option (right to buy)A Award	Director	AAward	+200K sh	—	—	200,000
2023-09-05	UNCYUnicycive Therapeutics, Inc. · Stock OptionsA Award	Director	AAward	+180K sh	—	—	180,000
2023-07-11	UNCYUnicycive Therapeutics, Inc. · Tranche B Warrants (right to buy)C Conversion	Director	CConversion	+11.6M sh	—	—	11,638,534
2023-07-11	UNCYUnicycive Therapeutics, Inc. · Tranche C Warrants (right to buy)C Conversion	Director	CConversion	+18.6M sh	—	—	18,621,655
2023-07-11	UNCYUnicycive Therapeutics, Inc.C Conversion	Director	CConversion	+3.47M sh	—	—	3,470,152
2023-07-11	UNCYUnicycive Therapeutics, Inc. · Series A-1 Preferred StockC Conversion	Director	CConversion	−8,077 sh	$1000.00	−$8.08M	0
2023-07-11	UNCYUnicycive Therapeutics, Inc. · Series A-2 Preferred StockC Conversion	Director	CConversion	+13.4M sh	—	—	13,429,000
2023-07-11	UNCYUnicycive Therapeutics, Inc. · Tranche A Warrants (right to buy)C Conversion	Director	CConversion	+12.8M sh	—	—	12,802,388
2023-03-08	UNCYUnicycive Therapeutics, Inc. · Series A-1 Convertible Preferred StockA Award	Director	AAward	+8,077 sh	$1000.00	+$8.08M	8,077
2022-07-01	Sierra Oncology, Inc.Series A WarrantD Disposition to Issuer	Director	DDisposition to Issuer	−1.46M sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−2.74M sh	$55.00	−$150M	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,874 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,500 sh	—	—	0
2022-01-31	Sierra Oncology, Inc.P Purchase	Director	PPurchase	+800K sh	$27.00	+$21.6M	2,735,853
2022-01-26	Sierra Oncology, Inc.Series B Warrant (Right to Purchase)X Exercise of In-Money	Director	XExercise of In-Money	−1.46M sh	$13.20	−$19.2M	0
2022-01-26	Sierra Oncology, Inc.X Exercise of In-Money	Director	XExercise of In-Money	+480K sh	$13.20	+$6.34M	1,935,853
2021-06-08	Sierra Oncology, Inc.Stock Option (Right To Buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2020-06-09	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Director	AAward	+6,874 sh	—	—	6,874
2020-01-29	Sierra Oncology, Inc.C Conversion	Director	CConversion	+1.46M sh	—	—	1,455,576
2020-01-29	Sierra Oncology, Inc.Series A Convertible Voting Preferred StockC Conversion	Director	CConversion	−19.2K sh	—	—	0
2019-11-29	Sierra Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2016-01-15	Ocera Therapeutics, Inc.P Purchase	Chief Business Officer	PPurchase	+10K sh	$2.15	+$21.5K	20,000
2016-01-06	Ocera Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+49.3K sh	—	—	49,325
2016-01-06	Ocera Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+148K sh	—	—	147,975
2015-06-18	Ocera Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+75K sh	—	—	75,000
2015-05-06	Ocera Therapeutics, Inc.P Purchase	Chief Business Officer	PPurchase	+7,500 sh	$3.62	+$27.2K	10,000
2012-07-31	HYPERION THERAPEUTICS INCP Purchase	Director	PPurchase	+5,000 sh	$10.00	+$50K	5,000

Recent filings

Accepted (ET)
Aug 264
Aggarwal Gaurav0001213900-25-080808
SEC(opens sec.gov)
Jul 304
Aggarwal Gaurav0001213900-25-069306
SEC(opens sec.gov)
May 224
Aggarwal Gaurav0000886744-25-000027
SEC(opens sec.gov)
Feb 194
Aggarwal Gaurav0001213900-25-015152
SEC(opens sec.gov)
Oct 104
Aggarwal Gaurav0001213900-24-086928
SEC(opens sec.gov)
May 104
Aggarwal Gaurav0000950170-24-057800
SEC(opens sec.gov)
Jan 34
Aggarwal Gaurav0001209191-24-000545
SEC(opens sec.gov)
Nov 284
Aggarwal Gaurav0001209191-23-056767
SEC(opens sec.gov)
Sep 74
Aggarwal Gaurav0001213900-23-075008
SEC(opens sec.gov)
Jul 134
Aggarwal Gaurav0001213900-23-056885
SEC(opens sec.gov)
Mar 94
Aggarwal Gaurav0001213900-23-018973
SEC(opens sec.gov)
Jul 14
Aggarwal Gaurav0001209191-22-040279
SEC(opens sec.gov)

Companies

Address

C/O HYPERION THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 200

SOUTH SAN FRANCISCO, CA, 94080